Homology Medicines Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 7

Employees

  • Latest Deal Type
  • M&A

Homology Medicines General Information

Description

Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Corporate Office
  • One Patriots Park
  • Bedford, MA 01730
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Homology Medicines Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 25-Mar-2024 00000 Completed Generating Revenue
6. PIPE 14-Nov-2020 0000 00000 00000 Completed Generating Revenue
5. 2PO 12-Apr-2019 00000 00000 Completed Generating Revenue
4. IPO 28-Mar-2018 00000 00000 00000 Completed Generating Revenue
3. Early Stage VC (Series B) 01-Aug-2017 000.00 00000 00000 Completed Startup
2. Early Stage VC (Series A) 02-May-2016 $43.5M $43.5M 000.00 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Homology Medicines’s complete valuation and funding history, request access »

Homology Medicines Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Homology Medicines’s complete cap table history, request access »

Homology Medicines Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patient
Biotechnology
Bedford, MA
7 As of 2023
00000
000000&0 00000

000000

ipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
0000000000000
Rockville, MD
000 As of 0000
00000
00000000 00000

000000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qu
0000000000000
Berkeley, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Homology Medicines Competitors (91)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regenxbio Formerly VC-backed Rockville, MD 000 00000 00000000 00000
Caribou Biosciences Formerly VC-backed Berkeley, CA 000 00000 00000000 00000
Rocket Pharmaceuticals Formerly VC-backed Cranbury, NJ 000 00000 00000000 00000
Neuron23 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
Recursion Pharmaceuticals Formerly VC-backed Salt Lake City, UT 000 00.000 000000000 00.000
You’re viewing 5 of 91 competitors. Get the full list »

Homology Medicines Patents

Homology Medicines Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230399657-A1 Liver de-targeted recombinant aav capsid proteins Pending 17-May-2022 000000000
US-20230374546-A1 Bidirectional dual promoter expression vectors and uses thereof Pending 11-Mar-2022 000000000
US-20230323395-A1 Methods and compositions for the production of adeno-associated virus Pending 15-Dec-2021 000000000
US-20230183659-A1 Methods and compositions for the purification of adeno-associated virus Pending 29-Oct-2021 00000000
US-20230112648-A1 Non-naturally occurring polyadenylation elements and methods of use thereof Pending 17-Sep-2021 C12N15/63
To view Homology Medicines’s complete patent history, request access »

Homology Medicines Executive Team (18)

Name Title Board Seat Contact Info
Paul Alloway Chief Executive Officer & Chief Operating Officer, Operations
Charles Michaud Jr. Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Michael Blum Executive
Saswati Chatterjee Ph.D Scientific Founder and Co-founder, Homology Medicines & City of Hope
Julie Jordan Chief Medical Officer
You’re viewing 5 of 18 executive team members. Get the full list »

Homology Medicines Board Members (14)

Name Representing Role Since
Alise Reicin MD Self Board Member 000 0000
Cameron Wheeler Ph.D Deerfield Management Board Member 000 0000
Jeffrey Poulton Self Board Member 000 0000
Kush Parmar Ph.D 5AM Ventures Chairman & Board Member 000 0000
Mary Thistle Homology Medicines Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Homology Medicines Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Homology Medicines Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
4:59 Initiative Accelerator/Incubator Minority 000 0000 000000 0
5AM Ventures Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Alexandria Venture Investments Venture Capital Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

Homology Medicines Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Q32 Bio 25-Mar-2024 0000000 00 Drug Discovery
Oxford Biomedica Solutions 10-Mar-2022 Joint Venture 0000 Drug Discovery 000000 00
To view Homology Medicines’s complete investments and acquisitions history, request access »

Homology Medicines FAQs

  • When was Homology Medicines founded?

    Homology Medicines was founded in 2015.

  • Who is the founder of Homology Medicines?

    Saswati Chatterjee Ph.D is the founder of Homology Medicines.

  • Who is the CEO of Homology Medicines?

    Paul Alloway is the CEO of Homology Medicines.

  • Where is Homology Medicines headquartered?

    Homology Medicines is headquartered in Bedford, MA.

  • What is the size of Homology Medicines?

    Homology Medicines has 7 total employees.

  • What industry is Homology Medicines in?

    Homology Medicines’s primary industry is Biotechnology.

  • Is Homology Medicines a private or public company?

    Homology Medicines is a Private company.

  • What is Homology Medicines’s current revenue?

    The current revenue for Homology Medicines is 000000.

  • How much funding has Homology Medicines raised over time?

    Homology Medicines has raised $456M.

  • Who are Homology Medicines’s investors?

    4:59 Initiative, 5AM Ventures, ARCH Venture Partners, Alexandria Venture Investments, and Deerfield Management are 5 of 16 investors who have invested in Homology Medicines.

  • Who are Homology Medicines’s competitors?

    Regenxbio, Caribou Biosciences, Rocket Pharmaceuticals, Neuron23, and Recursion Pharmaceuticals are some of the 91 competitors of Homology Medicines.

  • When was Homology Medicines acquired?

    Homology Medicines was acquired on 25-Mar-2024.

  • Who acquired Homology Medicines?

    Homology Medicines was acquired by Q32 Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »